⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL432000 | 1.00 | — | — | |
| SCHEMBL4640293 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL28245185 | 0.98 | KDM4E (0.41) | — | |
| SCHEMBL30476298 | 0.93 | KDM4E (0.41) | — | |
| SCHEMBL1127260 | 0.86 | — | — | |
| SCHEMBL1479975 | 0.86 | — | — | |
| SCHEMBL4641631 | 0.86 | — | — | |
| SCHEMBL16612025 | 0.82 | MAPT (0.42) | — | |
| SCHEMBL2916111 | 0.81 | HDAC3 (0.37) | — | |
| SCHEMBL16228066 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516039-B2 | N-linked isoquinoline amides as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-01-06 | — | — | US | claimed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| US-20230406844-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | US | claimed |
| EP-4236950-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2023-09-06 | — | — | EP | claimed |
| CN-116390727-A | N-linked isoquinolinamides as LRRK2 inhibitors, pharmaceutical compositions and uses thereof | 默沙东有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| EP-3759085-B1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE LLC (US) | 2022-12-14 | — | — | EP | claimed |
| WO-2022093881-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | claimed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| WO-2010034796-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | claimed |
| US-12516039-B2 | N-linked isoquinoline amides as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4536653-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | Eisai R&D Management Co., Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| WO-2024126777-A1 | HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| CN-118044519-A | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20090018122-A1 | Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-15 | — | — | US | disclosed |
| CN-1839204-A | Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof | UNIV NEW YORK (US) | 2006-09-27 | — | — | CN | disclosed |
| EP-1242055-A1 | HYDROGEL-DRIVEN DRUG DOSAGE FORM | Pfizer Products Inc. (US) | 2002-09-25 | — | — | EP | disclosed |
| EP-1239835-A1 | PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS | Pfizer Products Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001047495-A1 | PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS | PFIZER PRODUCTS INC. (US) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001047500-A1 | HYDROGEL-DRIVEN DRUG DOSAGE FORM | PFIZER PRODUCTS INC. (US) | 2001-07-05 | — | — | WO | disclosed |